MYGN241220C31000
- 0.00
- 0.000.00%
Myriad Genetics Newsroom
Myriad Genetics Expands Partnership With Illumina to Enhance Genomic Profiling for Cancer Detection
Myriad Genetics Announces The Incorporation Of Its HRD Platform In Illumina's Updated Gene Panel Assay
Myriad Genetics Announces Incorporation of Its Proprietary HRD Platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight Oncology 500 V2
Myriad Genetics Announces Prequel Prenatal Screening Can Now Be Performed Eight Weeks Into Pregnancy
Morgan Stanley Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $21
Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
MYGN Stock Might Gain From SneakPeek Availability in Retail Stores
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test With Retail Launch
Scotiabank Maintains Myriad Genetics(MYGN.US) With Buy Rating, Cuts Target Price to $24
Earnings Release: Here's Why Analysts Cut Their Myriad Genetics, Inc. (NASDAQ:MYGN) Price Target To US$25.69
Express News | Myriad Genetics Inc : Scotiabank Cuts Target Price to $24 From $34
Myriad Genetics Is Maintained at Neutral by Piper Sandler
Myriad Genetics Analyst Ratings
J.P. Morgan Maintains Myriad Genetics(MYGN.US) With Sell Rating, Cuts Target Price to $15
Piper Sandler Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $24
Analysts Offer Insights on Healthcare Companies: Myriad Genetics (MYGN) and Jazz Pharmaceuticals (JAZZ)
Myriad Genetics: Overcoming Setbacks With Strategic Resilience and Growth Prospects
Myriad Genetics, Inc. (MYGN) Q3 2024 Earnings Call Transcript Summary
Myriad Genetics Reports Solid Q3 2024 Growth Amid Challenges
TD Cowen Maintains Myriad Genetics(MYGN.US) With Hold Rating, Maintains Target Price $20